1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Zurzuvae |
| structure | File | |
| classes | List of String, delimiter: , | Neuroactive steroid • GABA-A positive allosteric modulator (oral) |
| mechanism | String | Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. |
| uses | String | Postpartum depression (PPD) in adults (FDA-approved 2023) |
| starting_dose | String | 50 mg PO once daily with fatty food in the evening × 14 days |
| preparations | String | 20 mg, 25 mg, 30 mg capsules |
| fda_max | String | 50 mg/d × 14 d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Day 3 of dosing in trials; sustained through day 45 |
| duration | String | 14-day course; effect persists after discontinuation in trials |
| halflife | String | ~16-23 hours |
| bioavailability | String | Adequate (food-dependent, must take with fatty meal) |
| pregnancy | String | Limited data; avoid in pregnancy. Lactation: present in milk; consider risks |
| legal | String | Rx, Schedule IV (US) |
